In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cottage Industry Patent Suits Against Device Companies Likely To Rise

This article was originally published in The Gray Sheet

Executive Summary

The growth in medical device patent lawsuits corresponds to the increase in patents issued to device companies, but lawsuits from "patent companies" will likely increase, Foley & Lardner attorney Andy Rawlins says

You may also be interested in...



Boston Scientific Loses $501 Million Stent Patent Case To Physician

A Texas jury decided Feb. 12 that Boston Scientific should pay a New Jersey radiologist $501 million for infringing a patent related to drug-eluting stents

Patent Bill Damages Provision Still Up For Debate – Senate Committee Report

A Senate Judiciary Committee 1report on a pending patent reform bill suggests a controversial provision on calculating infringement damages is still ripe for revision, but bill authors will not stray too far from their original intent

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel